Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMF-500 |
Synonyms | |
Therapy Description |
BMF-500 is a covalent FLT3 inhibitor, which reduces downstream signaling and potentially decreases tumor growth (Blood (2022) 140 (Supplement 1): 6191-6192). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMF-500 | BMF500|BMF 500 | FLT3 Inhibitor 69 | BMF-500 is a covalent FLT3 inhibitor, which reduces downstream signaling and potentially decreases tumor growth (Blood (2022) 140 (Supplement 1): 6191-6192). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 act mut | acute myeloid leukemia | predicted - sensitive | BMF-500 | Preclinical | Actionable | In a preclinical study, BMF-500 inhibited Flt3 phosphorylation and downstream signaling and decreased viability of acute myeloid leukemia cell lines harboring FLT3 activating mutations in culture and induced tumor regression and improved survival in xenograft models (Blood (2022) 140 (Supplement 1): 6191-6192). | detail... |
FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | BMF-500 | Preclinical - Patient cell culture | Actionable | In a preclinical study, BMF-500 decreased viability of patient-derived acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture (Blood (2022) 140 (Supplement 1): 6191-6192). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05918692 | Phase I | BMF-500 | A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | Recruiting | USA | 0 |